Ovate Pontic Versus Essix Provisional After Tooth Extraction and Alveolar Ridge Preservation (Pontic-Essix) (Pontic-Essix)
Socket Sealing With a Fixed Ovate Pontic Provisional Versus a Removable Provisional Following Tooth Extraction and Alveolar Ridge Preservation: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Following tooth extraction, dimensional changes of the alveolar ridge and loss of interproximal soft tissue height may compromise esthetic and prosthetic outcomes. Alveolar ridge preservation attenuates hard tissue resorption but provides limited active support for the overlying soft tissues during healing. An ovate pontic provisional restoration may provide active soft tissue support and thereby help preserve interproximal soft tissue height. To date, no randomized controlled trial has compared a fixed ovate pontic provisional restoration with a removable non-contact Essix provisional restoration in the context of alveolar ridge preservation.
This is a single-center, open-label, confirmatory, randomized controlled trial with two parallel groups and 1:1 allocation. An adaptive design with an internal pilot phase (n=20) and blinded sample size re-estimation based on the residual variance of the primary endpoint is applied, up to a predefined maximum of 40 participants.
All participants undergo minimally traumatic, flapless single non-molar tooth extraction and alveolar ridge preservation with Bio-Oss Collagen. Test group: socket sealing by a fixed, 3D-printed ovate pontic provisional restoration providing active soft tissue support. Control group: socket sealing with Mucograft Seal plus a removable Essix-type provisional restoration positioned without intentional soft tissue contact.
Follow-up visits are performed at 2 weeks, 4 weeks, and 5 months. At baseline (T0) and at 5 months, intraoral surface scans, clinical photographs, cone-beam computed tomography, and patient-reported outcomes are collected. The between-group treatment effect on the primary endpoint is estimated using ANCOVA with the 5-month value as dependent variable, treatment group as fixed factor, and the baseline value as covariate; jaw is included as an additional between-subject factor.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nicole Schenk, Dr. med. dent.
- Phone Number: +41 31 684 06 35
- Email: nicole.schenk@unibe.ch
Study Contact Backup
- Name: Martin Schimmel, Prof. Dr. med. dent.
- Phone Number: +41 31 684 06 35
- Email: martin.schimmel@unibe.ch
Study Locations
-
-
Canton of Bern
-
Bern, Canton of Bern, Switzerland, 3010
- University of Bern, Department of Reconstructive Dentistry and Gerodontology
-
Contact:
- Nicole Schenk, Dr. med. dent.
- Phone Number: +41 31 684 06 35
- Email: nicole.schenk@unibe.ch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged 18 years or older
- ASA physical status I or II
- Requiring a single non-molar tooth extraction (incisor, canine, or premolar) in the maxilla or mandible, with planned tooth replacement
- Extraction site bounded by natural, periodontally stable adjacent teeth
- Intact alveolar socket upon extraction, or no more than one bony wall (facial, palatal, or lingual) presenting a dehiscence extending less than 50% of the total bony wall height
- Willingness and ability to comply with the follow-up protocol
- Ability to give informed consent, as documented by signature
Exclusion Criteria:
- Current smokers, or former smokers who quit less than 6 months before extraction
- Uncontrolled diabetes mellitus (HbA1c > 7.0%)
- Clinical attachment loss ≥ 2 mm at the extraction site
- Active or recent chemotherapy, or history of head and neck radiotherapy
- Current or previous bisphosphonate therapy within the past 10 years
- Immunosuppressive medication
- Active oral or systemic acute infection
- Severe hematologic disorder, hepatic or renal failure, or any clinically relevant bleeding disorder or anticoagulant medication that cannot be safely managed for the planned surgical procedure
- Pregnancy or lactation
- Known allergy or hypersensitivity to any of the study materials, including bovine-derived bone substitute, porcine-derived collagen matrix, or collagen-containing biomaterials
- Any other disease or medication that may compromise normal wound healing
- Inability to follow the study procedures (e.g., insufficient language comprehension, cognitive impairment, psychological disorder, or dementia)
- Known or suspected non-compliance
- Participation in another clinical trial that may interfere with the present study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fixed ovate pontic provisional
Following minimally traumatic, flapless tooth extraction, the alveolar socket is grafted with Bio-Oss Collagen.
Socket sealing is achieved by a fixed, 3D-printed provisional restoration incorporating an ovate pontic design that extends approximately 2 mm apical to the mucosal margin, providing active soft tissue support to maintain interproximal papilla height and facial soft tissue contour during healing.
The provisional is retained by adhesive bonding or temporary cementation on the adjacent teeth.
No additional collagen matrix or sutures are placed.
|
Deproteinized bovine bone mineral with 10% collagen (Geistlich Pharma AG, Wolhusen, Switzerland).
Used for alveolar ridge preservation by socket grafting after tooth extraction.
CE-marked and used within the approved indication.
Other Names:
Patient-specific 3D-printed provisional restoration (PMMA or comparable clinically approved dental provisional material) incorporating an ovate pontic design.
Retained by adhesive bonding or temporary cementation on the adjacent teeth.
The convex, highly polished pontic extends approximately 2 mm apical to the mucosal margin and above the level of the bone graft, providing active soft tissue support.
|
|
Active Comparator: Removable Essix provisional with collagen matrix seal
Following minimally traumatic, flapless tooth extraction, the alveolar socket is grafted with Bio-Oss Collagen.
The socket is sealed with a porcine-derived collagen matrix (Mucograft Seal) secured with four to six single interrupted sutures, without primary closure.
A removable Essix-type provisional restoration with an integrated artificial tooth is delivered; the pontic is positioned above the mucosal level without intentional soft tissue contact.
|
Deproteinized bovine bone mineral with 10% collagen (Geistlich Pharma AG, Wolhusen, Switzerland).
Used for alveolar ridge preservation by socket grafting after tooth extraction.
CE-marked and used within the approved indication.
Other Names:
Patient-specific 3D-printed provisional restoration (PMMA or comparable clinically approved dental provisional material) incorporating an ovate pontic design.
Retained by adhesive bonding or temporary cementation on the adjacent teeth.
The convex, highly polished pontic extends approximately 2 mm apical to the mucosal margin and above the level of the bone graft, providing active soft tissue support.
Patient-specific removable thermoplastic Essix-type appliance with an integrated artificial tooth.
The pontic is positioned above the mucosal level without intentional soft tissue contact.
Delivered at the surgical visit after socket sealing with the collagen matrix.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interproximal soft tissue height at 5 months
Time Frame: Baseline (T0) and 5 months after tooth extraction
|
Interproximal soft tissue height at 5 months, calculated per participant as the mean of the mesial and distal measurements and expressed in millimeters.
Measurements are obtained by digital superimposition of baseline and 5-month intraoral surface scans (Geomagic Control X, 3D Systems) by an independent, calibrated examiner.
The between-group treatment effect is estimated using ANCOVA with the 5-month value as the dependent variable, treatment group as a fixed factor, baseline value as a covariate, and jaw as an additional between-subject factor.
|
Baseline (T0) and 5 months after tooth extraction
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Midfacial mucosal level at 5 months
Time Frame: Baseline (T0) and 5 months
|
Vertical position of the midfacial mucosal margin at 5 months (mm), assessed on superimposed intraoral surface scans.
The between-group difference is estimated using ANCOVA with the 5-month value as dependent variable and the baseline value as covariate.
|
Baseline (T0) and 5 months
|
|
Horizontal ridge contour at 5 months
Time Frame: Baseline (T0) and 5 months
|
Horizontal ridge contour at 5 months (mm) at 1, 3, and 5 mm apical to the baseline mucosal reference, assessed on superimposed intraoral surface scans.
Baseline-adjusted analysis at each level.
|
Baseline (T0) and 5 months
|
|
Mucosal thickness at 5 months
Time Frame: Baseline (T0) and 5 months
|
Mucosal thickness at 5 months (mm) at 1, 3, and 5 mm apical to the baseline mucosal reference.
Baseline-adjusted analysis at each level
|
Baseline (T0) and 5 months
|
|
Volumetric soft tissue at 5 months
Time Frame: Baseline (T0) and 5 months
|
Volumetric soft tissue measurement at 5 months (mm3) within the defined region of interest, assessed on superimposed intraoral surface scans.
Baseline-adjusted analysis.
|
Baseline (T0) and 5 months
|
|
Alveolar hard tissue volume at 5 months
Time Frame: Baseline (T0) and 5 months
|
Volumetric measurement of alveolar hard tissue at 5 months (mm3), assessed on superimposed CBCT data.
Baseline-adjusted analysis.
|
Baseline (T0) and 5 months
|
|
Alveolar hard tissue contour at 5 months
Time Frame: Baseline (T0) and 5 months
|
Linear measurement of alveolar hard tissue contour at 5 months (mm), assessed on superimposed CBCT data.
Baseline-adjusted analysis.
|
Baseline (T0) and 5 months
|
|
Postoperative discomfort (VAS)
Time Frame: 2 weeks and 4 weeks after tooth extraction
|
Postoperative discomfort assessed on a 100-mm visual analogue scale, ranging from 0 mm (no discomfort) to 100 mm (worst imaginable discomfort).
|
2 weeks and 4 weeks after tooth extraction
|
|
Patient satisfaction with function (VAS)
Time Frame: 5 months
|
Patient-rated satisfaction with the function of the provisional restoration, assessed on a 100-mm visual analogue scale, ranging from 0 mm (completely unsatisfied) to 100 mm (completely satisfied).
|
5 months
|
|
Patient satisfaction with esthetics (VAS)
Time Frame: 5 months
|
Patient-rated satisfaction with the esthetics of the provisional restoration, assessed on a 100-mm visual analogue scale, ranging from 0 mm (completely unsatisfied) to 100 mm (completely satisfied).
|
5 months
|
|
Patient satisfaction with comfort (VAS)
Time Frame: 5 months
|
Patient-rated satisfaction with the comfort of the provisional restoration, assessed on a 100-mm visual analogue scale, ranging from 0 mm (completely unsatisfied) to 100 mm (completely satisfied).
|
5 months
|
|
Overall treatment satisfaction (VAS)
Time Frame: 5 months
|
Patient-rated overall satisfaction with the treatment received, assessed on a 100-mm visual analogue scale, ranging from 0 mm (completely unsatisfied) to 100 mm (completely satisfied).
|
5 months
|
|
Willingness to undergo the same procedure again (VAS)
Time Frame: 5 months
|
Patient-rated willingness to undergo the same procedure again, assessed on a 100-mm visual analogue scale, ranging from 0 mm (definitely not) to 100 mm (definitely yes).
|
5 months
|
|
Oral Health Impact Profile (OHIP-G14)
Time Frame: Baseline (T0) and 5 months
|
German version of the Oral Health Impact Profile, 14-item version.
Summary score range 0 to 56; higher scores indicate worse oral health-related quality of life.
|
Baseline (T0) and 5 months
|
|
Geriatric Oral Health Assessment Index (GOHAI)
Time Frame: Baseline (T0) and 5 months
|
German version of the Geriatric Oral Health Assessment Index.
Summary score range 12 to 60; higher scores indicate better oral health-related quality of life.
|
Baseline (T0) and 5 months
|
|
Adverse events and provisional-related complications
Time Frame: Up to 5 months
|
Occurrence and rate of adverse events, including postoperative infection, impaired wound healing, soft tissue dehiscence, loss or displacement of the bone substitute or collagen matrix, allergic or hypersensitivity reactions, pressure-induced mucosal lesions, debonding of the fixed provisional restoration, or irritation related to the Essix provisional.
|
Up to 5 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nicole Schenk, Dr. med. dent., University of Bern, Department of Reconstructive Dentistry and Gerodontology
- Study Chair: Martin Schimmel, Prof. Dr. med. dent., University of Bern, Department of Reconstructive Dentistry and Gerodontology
- Study Director: Emilio Couso-Queiruga, PD Dr. med. dent., University of Bern, Department of Oral Surgery and Stomatology
Publications and helpful links
General Publications
- Avila-Ortiz G, Gubler M, Romero-Bustillos M, Nicholas CL, Zimmerman MB, Barwacz CA. Efficacy of Alveolar Ridge Preservation: A Randomized Controlled Trial. J Dent Res. 2020 Apr;99(4):402-409. doi: 10.1177/0022034520905660. Epub 2020 Feb 12.
- Couso-Queiruga E, Garaicoa-Pazmino C, Fonseca M, Chappuis V, Gonzalez-Martin O, Avila-Ortiz G. Interproximal Soft Tissue Height Changes After Unassisted Socket Healing vs Alveolar Ridge Preservation Therapy. Int J Periodontics Restorative Dent. 2024;44(5):520-533. doi: 10.11607/prd.6809.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pontic-Essix
- 2026-01626 (Other Identifier: Swiss Ethics Committee (BASEC))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.